Atherosclerotic cardiovascular disease, usually abbreviated ASCVD, is the umbrella term for heart attacks, strokes, and peripheral artery disease caused by the buildup of fatty plaques inside artery walls. It remains the leading cause of death worldwide, yet the biology behind it turns out to be far more layered than “cholesterol clogs your pipes.” Inflammation, immune-cell behavior, genetics, and even gut bacteria all shape whether a plaque sits quietly for decades or ruptures without warning.
How a Plaque Forms
The process starts when low-density lipoprotein particles, the familiar “bad cholesterol,” slip through the inner lining of a medium or large artery and become trapped in the vessel wall. Once stuck there, these particles get chemically modified by oxidation. Oxidized LDL acts as an alarm signal: it attracts white blood cells, particularly monocytes, which cross the artery lining and transform into macrophages. Those macrophages gorge on the oxidized lipids and balloon into what pathologists call foam cells.
Foam cells are central to the disease. They drive both the inflammatory response and the physical growth of the plaque. Recent single-cell studies have identified distinct subtypes of foam cells within plaques, some resembling resident tissue cells, others highly inflammatory, and still others expressing a receptor called Trem2 at high levels. Foam cells eventually die through several programmed-death pathways, and when the debris is not efficiently cleared, it accumulates into a soft, necrotic core inside the plaque.
Over years or decades, a fibrous cap of smooth-muscle cells and collagen forms over this core, walling it off from the blood. At this stage the artery may be noticeably narrowed, but the real danger is not the narrowing itself. It is what happens if the cap breaks open.
What Makes a Plaque Dangerous
Not all plaques are equal. Some are heavily calcified and stable, more rock than jelly. Others have thin fibrous caps, large lipid cores, and heavy immune-cell infiltration. These “vulnerable” plaques can rupture suddenly, exposing the necrotic core to flowing blood. The body treats this the way it treats any wound: it forms a clot. If the clot is large enough to block the artery, the tissue downstream dies. In a coronary artery that means a heart attack; in a brain artery, a stroke.
An imaging study comparing plaque rupture with plaque erosion (a different, less dramatic type of surface disruption) found that rupture was associated with significantly higher inflammation not just at the rupture site but across all three major coronary arteries. That widespread, “pancoronary” inflammation helps explain why heart attacks sometimes seem to come out of nowhere in people who appear otherwise stable.
Predicting Your Risk
Because ASCVD often strikes without warning symptoms, clinicians use risk calculators to estimate the probability of a first event over the next ten years. The most widely used tool in the United States is the Pooled Cohort Equations, endorsed by the American College of Cardiology and the American Heart Association. It weighs age, sex, race, total and HDL cholesterol, blood pressure, diabetes status, and smoking. A ten-year predicted risk of 7.5 percent or higher generally triggers a conversation about statin therapy.
The calculator has a known problem, though: it tends to overestimate risk. A large validation study in a contemporary, multiethnic population found that in every predicted risk category, the actual observed event rate was substantially lower than the tool predicted, with a C statistic (a measure of how well the model distinguishes who will and will not have an event) of about 0.74. That overestimation means some people end up on medication they may not need, while others in lower predicted-risk brackets slip through.
Alternative calculators exist. A scoping review of available tools found that no single calculator dominates across all populations: QRISK performs well in some cohorts, while the WHO/ISH charts score poorly, and the ACC/AHA equations overestimate in certain ethnic groups. Machine-learning models have shown promise in research settings. One study using data from a large multiethnic cohort found that a machine-learning calculator recommended statins to only about 11 percent of participants (versus 46 percent with the ACC/AHA tool) yet caught a higher proportion of actual events, with an area under the curve of 0.92 compared with 0.71.
When the Standard Calculator Is Not Enough
For people whose predicted risk falls in an intermediate zone, additional tests can sharpen the estimate. Coronary artery calcium scoring, a quick CT scan that quantifies calcified plaque in the heart’s arteries, is one of the best-validated add-ons. In the Rotterdam Study, calcium scoring reclassified more than half of intermediate-risk men and women into more accurate risk categories. A JAMA analysis later confirmed that adding the calcium score to the standard equations produced meaningful reclassification improvement, while adding a polygenic risk score did not significantly improve prediction beyond what was already captured.
Calcium scoring is most useful when you are on the fence about treatment. A score of zero in a middle-aged adult is strongly reassuring: it does not mean zero risk forever, but the near-term likelihood of a heart attack is very low. A high score, on the other hand, can motivate both patient and doctor to intensify prevention even if the standard calculator says risk is moderate.
Lipid Markers Beyond LDL
LDL cholesterol gets most of the attention, and lowering it is the backbone of ASCVD prevention. But it is not the whole story. Lipoprotein(a), often written Lp(a), is a genetically determined particle that resembles LDL but carries additional prothrombotic and proinflammatory properties. Evidence from genetic, observational, and mechanistic studies points to a causal link between elevated Lp(a) and both ASCVD and calcific aortic valve disease. Unlike LDL, Lp(a) levels are mostly set by your genes and do not respond well to statins or lifestyle changes. Therapies specifically targeting Lp(a) are in late-stage clinical trials.
Remnant cholesterol, the cholesterol carried by triglyceride-rich lipoproteins, is another underappreciated contributor. A study in the European Heart Journal found that elevated remnant cholesterol predicted ASCVD events independently of both LDL cholesterol and apolipoprotein B. People with high remnant cholesterol but low LDL had about a 21 percent higher risk of events compared with a reference group, even after adjusting for traditional risk factors. The finding matters because someone whose LDL looks fine on paper may still carry substantial lipid-driven risk if their triglyceride-rich particles are high.
How Statins Work Beyond Cholesterol Lowering
Statins remain the first-line drug for ASCVD prevention, and they do their job primarily by driving LDL cholesterol down. But research over the past two decades has shown they also stabilize existing plaques. By lowering the lipid content of the plaque core, statins reduce the substrate that fuels inflammation inside the artery wall. They also appear to dampen collagen-degrading enzyme activity, making the fibrous cap less likely to crack, and they reduce the blood’s tendency to clot.
Whether these plaque-stabilizing effects are truly independent of cholesterol lowering or simply a downstream consequence of it remains debated. Some laboratory evidence suggests statin-induced changes in small signaling proteins inside cells contribute to anti-inflammatory and antithrombotic effects at clinically relevant doses, but separating these “pleiotropic” effects from the lipid-lowering effect in living humans is difficult.
Newer Lipid-Lowering Options
When statins alone do not bring LDL low enough, or when side effects limit the dose, clinicians now have several add-on therapies. Ezetimibe blocks cholesterol absorption in the intestine and pairs well with a statin. PCSK9 inhibitors, injectable antibodies given every two to four weeks, can cut LDL by an additional 50 to 60 percent on top of statin therapy.
The newest entrant is inclisiran, a small interfering RNA molecule given as an injection just twice a year. It works by silencing the gene that produces PCSK9 in the liver. In pooled data from three large trials, inclisiran reduced LDL by about 51 percent versus placebo and was linked to a 24 percent reduction in cardiovascular events such as heart attack, stroke, and cardiac death. Long-term follow-up from the ORION-3 extension study showed that the LDL reduction was sustained over four years, with an average decrease of roughly 44 percent. A network meta-analysis comparing inclisiran to PCSK9 inhibitor antibodies and statin-plus-ezetimibe combinations found inclisiran ranked highest for LDL reduction, though it did not show a statistically significant difference from statin plus ezetimibe.
Anti-Inflammatory Therapy
If ASCVD is driven by inflammation as much as by cholesterol, it makes sense to ask whether anti-inflammatory drugs can reduce events. The answer, after four large trials enrolling over 25,000 patients, is a qualified yes. Canakinumab, an antibody that blocks the inflammatory cytokine interleukin-1β, reduced major cardiovascular events in patients with a prior heart attack and elevated C-reactive protein, but it also increased fatal infections, which made it impractical for routine use.
Colchicine, an old, inexpensive anti-inflammatory drug long used for gout, fared better on the safety front. Two trials tested low-dose colchicine (half a milligram daily) against placebo in patients with established coronary disease. Both showed reductions in major cardiovascular events. One trial reported a slight uptick in pneumonia; the other did not. Based on this evidence, low-dose colchicine became the first targeted anti-inflammatory therapy approved by the FDA specifically for ASCVD. It occupies a unique niche: it is not a lipid drug, and it addresses a dimension of the disease that statins alone do not fully control.
Drugs Originally Designed for Diabetes
Two drug classes developed for type 2 diabetes have turned out to protect blood vessels independently of their glucose-lowering effects. GLP-1 receptor agonists (the drug family that includes semaglutide and liraglutide) improve endothelial function, reduce inflammation and oxidative stress, and favorably remodel the heart. Large cardiovascular outcomes trials have consistently shown that several GLP-1 receptor agonists reduce heart attacks, strokes, cardiovascular death, and heart failure.
SGLT2 inhibitors, another diabetes drug class, have shown similarly striking cardiovascular benefits. In a large real-world analysis, patients on an SGLT2 inhibitor had about a 34 percent lower risk of cardiovascular events overall compared with those on other second-line diabetes therapies, with particularly large reductions in heart failure and stroke risk. Current guidelines now recommend both drug classes as early options for people with type 2 diabetes and established or high-risk cardiovascular disease. There are also early signals that their cardiovascular benefits may extend to primary prevention and to people without diabetes, though the evidence there is still maturing.
What You Eat and How You Move
No pill replaces the foundation of a healthy diet and regular physical activity. The Mediterranean diet, rich in olive oil, vegetables, legumes, fish, and whole grains, is the best-studied dietary pattern for cardiovascular protection. It lowers blood pressure, improves lipid profiles, reduces inflammation, and improves the function of the endothelium, the inner lining of blood vessels that is the first barrier against plaque formation. Stronger adherence to this eating pattern is consistently associated with lower rates of coronary heart disease, ischemic stroke, and total cardiovascular disease.
Exercise works on the vasculature in a direct mechanical way. When you move, blood flow speeds up and increases the shear stress on artery walls. That physical force stimulates the endothelium to release nitric oxide and growth factors, which in turn promote vessel relaxation, reduce stiffness, and boost the artery’s antioxidant defenses. A study in healthy men demonstrated that endothelial function improvements from exercise training were driven specifically by shear stress: when blood flow to one arm was blocked with a cuff during handgrip exercise, only the uncuffed arm showed improvement. The effect is not permanent without continued activity, but it accumulates over weeks and months of consistent training.
Why ASCVD Looks Different in Women
ASCVD has traditionally been characterized by studies in middle-aged men, and the clinical presentation can differ in women in ways that lead to underdiagnosis. Beyond the classic risk factors shared by both sexes, a woman’s reproductive history carries additional cardiovascular signals. Conditions such as polycystic ovary syndrome, gestational diabetes, preeclampsia, preterm delivery, and early menopause are all associated with increased future cardiovascular risk. The menopause transition itself represents a period of accelerated risk, driven by declining estrogen, unfavorable shifts in lipids and body composition, and increased arterial stiffness.
These reproductive risk factors do not cause ASCVD in a simple, linear way. They function more as stress tests: if the cardiovascular system is already vulnerable, pregnancy complications or early menopause may unmask that vulnerability sooner. Guidelines increasingly recognize these factors as “risk enhancers” that should be considered when the standard risk calculator puts a woman in the borderline zone.
Clonal Hematopoiesis and Other Emerging Risk Factors
One of the more surprising discoveries in recent cardiovascular research involves clonal hematopoiesis of indeterminate potential, or CHIP. This is a condition in which blood stem cells acquire mutations that give them a growth advantage, leading to an expanding clone of slightly abnormal blood cells. CHIP becomes increasingly common with age and has no symptoms of its own. Yet carriers of CHIP mutations had roughly double the risk of coronary heart disease in two prospective cohorts, and the risk was even higher in younger adults with early-onset heart attacks, where CHIP carriers had about four times the risk of noncarriers. Mouse experiments confirmed that one of the key mutations (in a gene called TET2) directly accelerated plaque growth and ramped up inflammatory signaling in macrophages.
The gut microbiome is another active area of investigation. Certain gut bacteria metabolize dietary nutrients such as choline and carnitine (found in red meat and eggs) into trimethylamine, which the liver converts to trimethylamine N-oxide, or TMAO. Elevated TMAO has been linked to endothelial dysfunction, platelet activation, and increased clot formation, all of which feed into the atherosclerotic process. It is still unclear whether TMAO is a direct driver or more of a bystander marker of an unhealthy diet, but it adds to the picture of ASCVD as a disease shaped by many systems beyond the artery wall itself.
An Ancient Disease, Not a Modern Invention
A common assumption is that ASCVD is a product of modern sedentary life and processed food. The evidence says otherwise. The HORUS study, a series of investigations using CT scans on mummified humans, found definite or probable atherosclerosis in about a third of 137 mummies from four geographically and culturally distinct preindustrial populations: ancient Egyptians, ancient Peruvians, Ancestral Puebloans of the American Southwest, and Unangan hunter-gatherers of the Aleutian Islands. The condition appeared across a time span of more than 4,000 years. An expanded global analysis of 237 mummies confirmed the finding, with atherosclerotic calcifications appearing at similar rates in men and women and across Egyptian and non-Egyptian populations.
The authors concluded that there appears to be an innate human predisposition to atherosclerosis, and that modern risk factors like smoking, obesity, and physical inactivity likely amplify the severity and consequences of a disease process that was already part of human biology long before any of those exposures existed. That reframing matters: it shifts the goal of prevention from “avoiding a modern disease” to “managing an ancient vulnerability.”
The Global Burden Is Shifting
Age-adjusted rates of ASCVD death and disability have been declining in high-income countries for decades, thanks to better prevention, treatment, and public-health measures. But in absolute terms, the number of people living with cardiovascular disease continues to rise because populations are growing and aging. And in low- and middle-income countries, the trend is moving in the opposite direction. An analysis of the 2021 Global Burden of Disease data found that high sociodemographic index regions reduced the ASCVD burden tied to lifestyle and metabolic risk factors over the past three decades, while low-index regions saw increases. Even in wealthier nations, there are signs that the rate of decline may be stalling, possibly because obesity and diabetes prevalence keep climbing.
This geographic and economic disparity means the tools and therapies discussed throughout this article are not equally accessible everywhere. A twice-yearly injection of inclisiran, a coronary calcium scan, or even reliable statin supply requires healthcare infrastructure and affordability that much of the world still lacks. Addressing ASCVD as a global problem will require not only better drugs but broader access to the basics: blood pressure management, tobacco control, and affordable healthy food.